1. Durable remission after ileocolic resection for Crohn's disease is achievable in selected patients. Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie.
- Author
-
Abdalla S, Benoist S, Maggiori L, Lefèvre JH, Denost Q, Cotte E, Germain A, Beyer-Berjot L, Desfourneaux V, Rahili A, Duffas JP, Pautrat K, Denet C, Bridoux V, Meurette G, Faucheron JL, Loriau J, Souche FR, Corte H, Vicaut É, Zerbib P, Panis Y, and Brouquet A
- Abstract
Background and Aims: Postoperative recurrence requiring medical treatment intensification or redo-surgery is common after ileocolic resection (ICR) for Crohn's disease (CD). This study aimed to identify a subgroup of CD patients for whom ICR could achieve durable remission., Methods: This retrospective follow-up study analyzed 592 CD patients who underwent ICR (2013-2015) in a nationwide prospective cohort. Patients with >36 months follow-up were included. Primary outcome was durable remission, defined as the absence of endoscopic recurrence and/or medical treatment intensification. Uni- and multivariate analyses identified predictive factors for durable remission., Results: Among 268 included patients, 59% had B2 phenotype, 70% had a first ICR and 66% had postoperative medical treatment. After a median follow-up of 85(36-104) months, 52 patients (19%) experienced durable remission, of whom 24 (46%) didn't require medical treatment and 28 (54%) maintained the same postoperative treatment, including anti-TNF in 15/28 patients (54%). Surgery could stabilize the disease course in 112 patients (41.7%), including 22.4% endoscopic recurrence that didn't require CD treatment initiation or intensification. Durable remission rate was significantly increased in B1 phenotype vs. B2/B3 (n=7/18;39% vs n=45/250;18%, p=0.030) and in first ICR vs. redo ICR (n=43/184;23% vs n=9/80;11%, p=0.023). In multivariate analysis, B1 phenotype was the only independent predictive factor for durable remission (OR=3.59, IC95%[1.13-11.37], p=0.030)., Conclusions: Surgery for CD achieved durable remission in 20%, rising to 40% in those with a B1 phenotype. These results support surgery as a viable alternative to medical treatment, offering treatment-free durable remission and preserving medical treatment options., (© The Author(s) 2025. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2025
- Full Text
- View/download PDF